Management of Coronary Atherosclerosis and Acute Coronary Syndromes in Patients With Chronic Kidney Disease

Current Problems in Cardiology

Volumn 38, Issue 5, 2013, Pages 165-206

  Narala, Karthiek R ^a   Hassan, Sohail ^a   LaLonde, Thomas A ^a   McCullough, Peter A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALBUMIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIANGINA PECTORIS AGENT; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; CLOPIDOGREL; CREATININE; DABIGATRAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ESMOLOL; FIBRINOGEN RECEPTOR ANTAGONIST; FLUINDOSTATIN; FONDAPARINUX; GLYCERYL TRINITRATE; LOW MOLECULAR WEIGHT HEPARIN; METOPROLOL TARTRATE; NITRIC ACID DERIVATIVE; PLACEBO; PRASUGREL; PRAVASTATIN; RANOLAZINE; RIVAROXABAN; TICAGRELOR; TROPONIN T; UNINDEXED DRUG;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ANGINA PECTORIS; ANGIOCARDIOGRAPHY; ARTICLE; BLEEDING; BLOOD PRESSURE REGULATION; BLOOD VESSEL CALCIFICATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CATHETER THROMBOSIS; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY DISEASE; CORONARY STENT; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE CONTROL; DISEASE COURSE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; EARLY DIAGNOSIS; GLOMERULUS FILTRATION RATE; HEALTH PROGRAM; HEART FAILURE; HEART INFARCTION; HEART MUSCLE INJURY; HEART MUSCLE NECROSIS; HEART MUSCLE REVASCULARIZATION; HEART REINFARCTION; HIGH RISK PATIENT; HUMAN; HYPERTENSION; INCIDENCE; KIDNEY FAILURE; LOADING DRUG DOSE; MICROALBUMINURIA; MORTALITY; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PATIENT CARE; PERCUTANEOUS CORONARY INTERVENTION; POPULATION RESEARCH; PRACTICE GUIDELINE; PREVALENCE; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK MANAGEMENT; SECONDARY PREVENTION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THROMBOEMBOLISM; UNSTABLE ANGINA PECTORIS;

ACUTE CORONARY SYNDROME; CARDIOVASCULAR AGENTS; CORONARY ARTERY DISEASE; FIBRINOLYTIC AGENTS; HUMANS; MYOCARDIAL INFARCTION; MYOCARDIAL REVASCULARIZATION; PRACTICE GUIDELINES AS TOPIC; RENAL INSUFFICIENCY, CHRONIC; RISK ASSESSMENT;

EID: 84876303828     PISSN: 01462806     EISSN: 15356280     Source Type: Journal    
DOI: 10.1016/j.cpcardiol.2012.12.004     Document Type: Article

References (133)

1. About chronic kidney disease, 2012 National Kidney Foundation, Accessed March 1, 2013. http://www.kidney.org/kidneydisease/aboutckd.cfm.
2. King S.B., Smith S.C., Hirshfeld J.W., et al. 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to review new evidence and update the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention, writing on behalf of the 2005 Writing Committee. Circulation 2008, 117:261-295.
3. Anderson J.L., Adams C.D., Antman E.M., et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 2002 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction) developed in collaboration with the American College of Emergency Physicians, the society for cardiovascular angiography and interventions, and the society of thoracic surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the society for academic emergency medicine. J Am Coll Cardiol 2007, 50:e1-e157.
4. McCullough P.A., Maynard R.C. Treatment disparities in acute coronary syndromes, heart failure, and kidney disease. Contrib Nephrol 2011, 171:68-73.
5. Madore F. Uremia-related metabolic cardiac risk factors in chronic kidney disease. Semin Dial 2003, 16:148-156.
6. Coca S.G., Krumholz H.M., Garg A.X., et al. Underrepresentation of renal disease in randomized controlled trials of cardiovascular disease. JAMA 2006, 296:1377-1384.
7. Inrig J.K., Patel U.D., Briley L.P., et al. Mortality, kidney disease and cardiac procedures following acute coronary syndrome. Nephrol Dial Transplant 2008, 23:934-940.
8. Brosius F.C., Hostetter T.H., Kelepouris E., et al. Detection of chronic kidney disease in patients with or at increased risk of cardiovascular disease: a science advisory from the American Heart Association kidney and cardiovascular Disease Council; the councils on high Blood Pressure research, cardiovascular disease in the young, and epidemiology and prevention; and the quality of care and outcomes research interdisciplinary Working Group: developed in collaboration with the national Kidney Foundation. Circulation 2006, 114:1083-1087.
9. Go A.S., Chertow G.M., Fan D., et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004, 351:1296-1305.
10. McCullough P.A., Li S., Jurkovitz C.T., et al. CKD and cardiovascular disease in screened high-risk volunteer and general populations: the kidney early evaluation program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999-2004. Am J Kidney Dis 2008, 51(4 suppl 2):S38-S45.
11. van der Velde M., Matsushita K., Coresh J., et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney Int 2011, 79:1341-1352.
12. USRDS, Annual Data Report: Atlas of End-Stage Renal Disease in the United States, 2005 US Renal Data System, Accessed March 1, 2013. http://www.usrds.org/atlas05.aspx.
13. Stevens L.A., Li S., Kurella Tamura M., et al. Comparison of the CKD Epidemiology Collaboration (CKD-EPI) and Modification of Diet in Renal Disease (MDRD) study equations: risk factors for and complications of CKD and mortality in the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis 2011, 57(3 Suppl 2):S9-S16.
14. Go A.S., Bansal N., Chandra M., et al. Chronic kidney disease and risk for presenting with acute myocardial infarction versus stable exertional angina in adults with coronary heart disease. J Am Coll Cardiol 2011, 58:1600-1607.
15. McCullough P.A., Nowak R.M., Foreback C., et al. Emergency evaluation of chest pain in patients with advanced kidney disease. Arch Intern Med 2002, 162:2464-2468.
16. Wattanakit K., Coresh J., Muntner P., et al. Cardiovascular risk among adults with chronic kidney disease, with or without prior myocardial infarction. J Am Coll Cardiol 2006, 48:1183-1189.
17. Rashidi A., Sehgal A.R., Rahman M., et al. The case for chronic kidney disease, diabetes mellitus, and myocardial infarction being equivalent risk factors for cardiovascular mortality in patients older than 65 years. Am J Cardiol 2008, 12:1668-1673.
18. El-Menyar A., Zubaid M., Sulaiman K., et al. In-hospital major clinical outcomes in patients with chronic renal insufficiency presenting with acute coronary syndrome: data from a registry of 8176 patients. Mayo Clin Proc 2010, 85:332-340.
19. Eagle K.A., Lim M.J., Dabbous O.H., et al. A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. JAMA 2004, 291:2727-2733.
20. Granger C.B., Goldberg R.J., Dabbous O., et al. Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med 2003, 163:2345-2353.
21. Das M., Aronow W.S., Mcclung J.A., et al. Increased prevalence of coronary artery disease, silent myocardial ischemia, complex ventricular arrhythmias, atrial fibrillation, left ventricular hypertrophy, mitral annular calcium, and aortic valve calcium in patients with chronic renal insufficiency. Cardiol Rev 2006, 14:14-17.
22. McCullough P.A., Soman S.S., Shah S.S., et al. Risks associated with renal dysfunction in patients in the coronary care unit. J Am Coll Cardiol 2000, 36:679-684.
23. Han J.H., Chandra A., Mulgund J., et al. Chronic kidney disease in patients with non-ST-segment elevation acute coronary syndromes. Am J Med 2006, 119:248-254.
24. Masoudi F.A., Plomondon M.E., Magid D.J., et al. Renal insufficiency and mortality from acute coronary syndromes. Am Heart J 2004, 147:623-629.
25. Yan A.T., Yan R.T., Tan M., et al. Treatment and one-year outcome of patients with renal dysfunction across the broad spectrum of acute coronary syndromes. Can J Cardiol 2006, 22:115-120.
26. Wison S., Foo K., Cunningham J., et al. Renal function and risk stratification in acute coronary syndromes. Am J Cardiol 2003, 91:1051-1054.
27. Jaffe A.S., Babuin L., Apple F.S. Biomarkers in acute cardiac disease: the present and the future. J Am Coll Cardiol 2006, 48:1-11.
28. Galvani M., Ottani F., Ferrini D., et al. Prognostic influence of elevated values of cardiac troponin I in patients with unstable angina. Circulation 1997, 95:2053-2059.
29. Freda B.J., Tang W.H., Van Lente F., et al. Cardiac troponins in renal insufficiency: review and clinical implications. J Am Coll Cardiol 2002, 40:2065-2071.
30. Mallamaci F., Zoccali C., Parlongo S., et al. Troponin is related to left ventricular mass and predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 2002, 40:68-75.
31. Aviles R.J., Askari A.T., Lindahl B., et al. Troponin T levels in patients with acute coronary syndromes, with or without renal dysfunction. N Engl J Med 2002, 346:2047-2052.
32. Newsome B.B., Warnock D.G., Kiefe C.I., et al. Delay in time to receipt of thrombolytic medication among Medicare patients with kidney disease. Am J Kidney Dis 2005, 46:595-602.
33. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002, 324:71-86. Antithrombotic Trialists' Collaboration.
34. Paoletti E., Cassottana P., Bellino D., et al. Left ventricular geometry and adverse cardiovascular events in chronic hemodialysis patients on prolonged therapy with ACE inhibitors. Am J Kidney Dis 2002, 40:728-736.
35. Shibasaki Y., Masaki H., Nishiue T., et al. Angiotensin II type 1 receptor antagonist, losartan, causes regression of left ventricular hypertrophy in end-stage renal disease. Nephron 2002, 90:256-261.
36. Wright R.S., Anderson J.L., Adams C.D., et al. 2011 ACCF/AHA Focused Update of the Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction (Updating the 2007 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011, 123:2022-2060.
37. Inrig J.K. Antihypertensive agents in hemodialysis patients: a current perspective. Semin Dial 2010, 23:290-297.
38. Baigent C., Landray M.J., Reith C., et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (study of heart and renal protection): a randomised placebo-controlled trial. Lancet 2011, 377:2181-2192.
39. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002, 360:7-22. Heart Protection Study Collaborative Group.
40. Sever P.S., Dahlöf B., Poulter N.R., et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian cardiac outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003, 361:1149-1158.
41. Shepherd J., Kastelein J.J., Bittner V., et al. Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the treating to new targets (TNT) study. Clin J Am Soc Nephrol 2007, 2:1131-1139.
42. Holdaas H., Fellström B., Jardine A.G., et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 2003, 361:2024-2031.
43. Jardine A.G., Holdaas H., Fellström B., et al. Fluvastatin prevents cardiac death and myocardial infarction in renal transplant recipients: post-hoc subgroup analyses of the ALERT study. Am J Transplant 2004, 4:988-995.
44. Tonelli M., Moyé L., Sacks F.M., et al. Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency. Ann Intern Med 2003, 138:98-104.
45. Ocak G., Vossen C.Y., Rotmans J.I., et al. Venous and arterial thrombosis in dialysis patients. Thromb Haemost 2011, 106:1046-1052.
46. Nampoory M.R., Das K.C., Johny K.V., et al. Hypercoagulability, a serious problem in patients with ESRD on maintenance hemodialysis, and its correction after kidney transplantation. Am J Kidney Dis 2003, 42:797-805.
47. Chew D.P., Bhatt D.L., Kimball W., et al. Bivalirudin provides increasing benefit with decreasing renal function: a meta-analysis of randomized trials. Am J Cardiol 2003, 92:919-923.
48. Wright R.S., Anderson J.L., Adams C.D., et al. 2011 ACCF/AHA focused update of the guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction (updating the 2007 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the American College of Emergency Physicians, society for cardiovascular angiography and interventions, and society of thoracic surgeons. J Am Coll Cardiol 2011, 57:1920-1959.
49. Medi C., Chew D.P., Amerena J., et al. An invasive management strategy is associated with improved outcomes in high-risk acute coronary syndromes in patients with chronic kidney disease. Int Med J 2011, 41:743-750.
50. Keeley E.C., Kadakia R., Soman S., et al. Analysis of long-term survival after revascularization in patients with chronic kidney disease presenting with acute coronary syndromes. Am J Cardiol 2003, 92509-92514.
51. Dragu R., Behar S., Sandach A., et al. Should primary percutaneous coronary intervention be the preferred method of reperfusion therapy for patients with renal failure and ST-elevation acute myocardial infarction?. Am J Cardiol 2006, 97:1142-1145.
52. Szummer K., Lundman P., Jacobson S.H., et al. Influence of renal function on the effects of early revascularization in non-ST-elevation myocardial infarction: data from the Swedish Web-System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies (SWEDEHEART). Circulation 2009, 120:851-858.
53. Wong J.A., Goodman S.G., Yan R.T., et al. Temporal management patterns and outcomes of non-ST elevation acute coronary syndromes in patients with kidney dysfunction. Eur Heart J 2009, 30:549-557.
54. Charytan D.M., Wallentin L., Lagerqvist B., et al. Early angiography in patients with chronic kidney disease: a collaborative systematic review. Clin J Am Soc Nephrol 2009, 4:1032-1043.
55. Kushner F.G., Hand M., Smith S.C., et al. 2009 Focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2009, 54:2205-2241.
56. Solomon R.J., Natarajan M.K., Doucet S., et al. Cardiac angiography in renally impaired patients (CARE) study: a randomized double-blind trial of contrast-induced nephropathy in patients with chronic kidney disease. Circulation 2007, 115:3189-3196.
57. Vandvik P.O., Lincoff A.M., Gore J.M., et al. Primary and secondary prevention of cardiovascular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012, 141:e637S-e668S.
58. Jeremias A., Bhatt D.L., Chew D.P., et al. Safety of abciximab during percutaneous coronary intervention in patients with chronic renal insufficiency. Am J Cardiol 2002, 89:1209-1211.
59. Frilling B., Zahn R., Fraiture B., et al. Comparison of efficacy and complication rates after percutaneous coronary interventions in patients with and without renal insufficiency treated with abciximab. Am J Cardiol 2002, 89:450-452.
60. Best P.J., Lennon R., Gersh B.J., et al. Safety of abciximab in patients with chronic renal insufficiency who are undergoing percutaneous coronary interventions. Am Heart J 2003, 146:345-350.
61. Freeman R.V., Mehta R.H., Al Badr W., et al. Influence of concurrent renal dysfunction on outcomes of patients with acute coronary syndromes and implications of the use of glycoprotein IIb/IIIa inhibitors. J Am Coll Cardiol 2003, 41:718-724.
62. Hamm C.W., Heeschen C., Goldmann B., et al. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina. (CAPTURE) Study Investigators. N Engl J Med 1999, 340:1623-1629.
63. Heeschen C., Hamm C.W., Goldmann B., et al. Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. PRISM study investigators. Platelet receptor inhibition in ischemic syndrome management. Lancet 1999, 354:1757-1762.
64. Tsai T.T., Maddox T.M., Roe M.T., et al. Contraindicated medication use in dialysis patients undergoing percutaneous coronary intervention. JAMA 2009, 302:2458-2464.
65. Palmer S.C., Di Micco L., Razavian M., et al. Effects of antiplatelet therapy on mortality and cardiovascular and bleeding outcomes in persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med 2012, 156:445-459.
66. Harrington R.A., Becker R.C., Cannon C.P., et al. Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008, 133:670S-707S.
67. Mehta S.R., Granger C.B., Eikelboom J.W., et al. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial. J Am Coll Cardiol 2007, 50:1742-1751.
68. Thorevska N., Amoateng-Adjepong Y., Sabahi R., et al. Anticoagulation in hospitalized patients with renal insufficiency: a comparison of bleeding rates with unfractionated heparin vs enoxaparin. Chest 2004, 125:856-863.
69. Lindahl B., Venge P., Wallentin L. Troponin T identifies patients with unstable coronary artery disease who benefit from long-term antithrombotic protection. Fragmin in unstable coronary artery disease (FRISC) Study Group. J Am Coll Cardiol 1997, 29:43-48.
70. Cohen M., Demers C., Gurfinkel E.P., et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and safety of subcutaneous enoxaparin in non-Q-Wave Coronary Events Study Group. N Engl J Med 1997, 337:447-452.
71. Busby L.T., Weyman A., Rodgers G.M. Excessive anticoagulation in patients with mild renal insufficiency receiving long-term therapeutic enoxaparin. Am J Hematol 2001, 67:54-56.
72. Gerlach A.T., Pickworth K.K., Seth S.K., et al. Enoxaparin and bleeding complications: a review in patients with and without renal insufficiency. Pharmacotherapy 2000, 20:771-775.
73. Yusuf S., Mehta S.R., Chrolavicius S., et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 2006, 354:1464-1476.
74. Stone G.W., Witzenbichler B., Guagliumi G., et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 2008, 358:2218-2230.
75. Stone G.W., Witzenbichler B., Guagliumi G., et al. Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial. Lancet 2011, 377:2193-2204.
76. Alexander J.H., Lopes R.D., James S., et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med 2011, 365:699-708.
77. Wallentin L., Wilcox R.G., Weaver W.D., et al. Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial. Lancet 2003, 362:789-797.
78. Oldgren J., Budaj A., Granger C.B., et al. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur Heart J 2011, 32:2781-2789.
79. Connolly S.J., Ezekowitz M.D., Yusuf S., et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009, 361:1139-1151.
80. Soman S.S., Sandberg K.R., Borzak S., et al. The independent association of renal dysfunction and arrhythmias in critically ill patients. Chest 2002, 122:669-677.
81. Beasley B.N., Unger E.F., Temple R. Anticoagulant options-why the FDA approved a higher but not a lower dose of dabigatran. N Engl J Med 2011, 364:1788-1790.
82. Mega J.L., Braunwald E., Wiviott S.D., et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012, 366:9-19.
83. Bauersachs R., Berkowitz S.D., Brenner B., et al. Oral Rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010, 363:2499-2510.
84. Gum P.A., Thamilarasan M., Watanabe J., et al. Aspirin use and all-cause mortality among patients being evaluated for known or suspected coronary artery disease: a propensity analysis. JAMA 2001, 286:1187-1194.
85. Fraker T.D., Fihn S.D., Gibbons R.J., et al. 2007 Chronic angina focused update of the ACC/AHA 2002 guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Writing Group to develop the focused update of the 2002 guidelines for the management of patients with chronic stable angina. Circulation 2007, 116:2762-2772.
86. Cice G., Ferrara L., D'Andrea A., et al. Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial. J Am Coll Cardiol 2003, 41:1438-1444.
87. Brophy J.M., Joseph L., Rouleau J.L. Beta-blockers in congestive heart failure. A bayesian meta-analysis. Ann Intern Med 2001, 134:550-560.
88. Agarwal R. Supervised atenolol therapy in the management of hemodialysis hypertension. Kidney Int 1999, 55:1528-1535.
89. Stegmayr B.G. Beta-blockers may cause ultrafiltration failure in peritoneal dialysis patients. Perit Dial Int 1997, 17:541-545.
90. Pitt B., Zannad F., Remme W.J., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone evaluation study investigators. N Engl J Med 1999, 341:709-717.
91. Pitt B., Remme W., Zannad F., et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003, 348:1309-1321.
92. Zannad F., McMurray J.J., Krum H., et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011, 364:11-21.
93. Nitrites and nitrates in the treatment of ischaemic heart disease. Br Med J 1967, 1:617-618.
94. Tislér A., Akócsi K., Hárshegyi I., et al. Comparison of dialysis and clinical characteristics of patients with frequent and occasional hemodialysis-associated hypotension. Kidney Blood Press Res 2002, 25:97-102.
95. Muntner P., Hamm L.L., Kusek J.W., et al. The prevalence of nontraditional risk factors for coronary heart disease in patients with chronic kidney disease. Ann Intern Med 2004, 140:9-17.
96. Shepherd J., Kastelein J.J., Bittner V., et al. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (treating to new targets) study. J Am Coll Cardiol 2008, 51:1448-1454.
97. Goicoechea M., de Vinuesa S.G., Lahera V., et al. Effects of atorvastatin on inflammatory and fibrinolytic parameters in patients with chronic kidney disease. J Am Soc Nephrol 2006, 17(12 Suppl 3):S231-S235.
98. Athyros V.G., Mikhailidis D.P., Papageorgiou A.A., et al. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J Clin Pathol 2004, 57:728-734.
99. Fellström B.C., Jardine A.G., Schmieder R.E., et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009, 360:1395-1407.
100. Wanner C., Krane V., März W., et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005, 353:238-248.
101. Chaitman B.R., Pepine C.J., Parker J.O., et al. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA 2004, 291:309-316.
102. Chaitman B.R., Skettino S.L., Parker J.O., et al. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol 2004, 43:1375-1382.
103. Morrow D.A., Scirica B.M., Karwatowska-Prokopczuk E., et al. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial. JAMA 2007, 297:1775-1783.
104. Jerling M. Clinical pharmacokinetics of ranolazine. Clin Pharmacokinet 2006, 45:469-491.
105. Jerling M., Abdallah H. Effect of renal impairment on multiple-dose pharmacokinetics of extended-release ranolazine. Clin Pharmacol Ther 2005, 78:288-297.
106. Chobanian A.V., Bakris G.L., Black H.R., et al. Seventh report of the joint National Committee on Prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003, 42:1206-1252.
107. Khouri Y., Steigerwalt S.P., Alsamara M., et al. What is the ideal blood pressure goal for patients with stage III or higher chronic kidney disease?. Curr Cardiol Rep 2011, 13:492-501.
108. Upadhyay A., Earley A., Haynes S.M., et al. Systematic review: blood pressure target in chronic kidney disease and proteinuria as an effect modifier. Ann Intern Med 2011, 154:541-548.
109. Khouri Y., Steigerwalt S.P., Alsamara M., et al. What is the ideal blood pressure goal for patients with stage III or higher chronic kidney disease?. Curr Cardiol Rep 2011, 13:492-501.
110. Peralta C.A., Norris K.C., Li S., et al. Blood pressure components and end-stage renal disease in persons with chronic kidney disease: the kidney early Evaluation Program (KEEP). Arch Intern Med 2012, 172:41-47.
111. Heerspink H.J., Ninomiya T., Zoungas S., et al. Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials. Lancet 2009, 373:1009-1015.
112. Agarwal R., Lewis R.R. Prediction of hypertension in chronic hemodialysis patients. Kidney Int 2001, 60:1982-1989.
113. Lynn K.L. Hypertension and survival in hemodialysis patients. Semin Dial 2004, 17:270-274.
114. Yusuf S., Sleight P., Pogue J., et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The heart outcomes prevention evaluation study investigators. N Engl J Med 2000, 342:145-153.
115. Lewis E.J., Hunsicker L.G., Clarke W.R., et al. Renoprotective effect of the angiotensin-receptor blocker irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001, 345:851-860.
116. Brenner B.M., Cooper M.E., de Zeeuw D., et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345:861-869.
117. Schmitt K.E., Edie C.F., Laflam P., et al. Adherence to antihypertensive agents and blood pressure control in chronic kidney disease. Am J Nephrol 2010, 32:541-548.
118. McCullough P.A., Agrawal V., Danielewicz E., et al. Accelerated atherosclerotic calcification and Monckeberg's sclerosis: a continuum of advanced vascular pathology in chronic kidney disease. Clin J Am Soc Nephrol 2008, 3:1585-1598.
119. McCullough P.A., Chinnaiyan K.M., Agrawal V., et al. Amplification of atherosclerotic calcification and Mönckeberg's sclerosis: a spectrum of the same disease process. Adv Chronic Kidney Dis 2008, 15:396-412.
120. McCullough P.A., Sandberg K.R., Dumler F., et al. Determinants of coronary vascular calcification in patients with chronic kidney disease and end-stage renal disease: a systematic review. J Nephrol 2004, 17:205-215.
121. McCullough P.A. Effect of lipid modification on progression of coronary calcification. J Am Soc Nephrol 2005, S115-S119.
122. McCullough P.A., Chinnaiyan K.M. Annual progression of coronary calcification in trials of preventive therapies: a systematic review. Arch Intern Med 2009, 169:2064-2070.
123. Raggi P., Chertow G.M., Torres P.U., et al. The ADVANCE study: a randomized study to evaluate the effects of Cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Nephrol Dial Transplant 2011, 26(4):1327-1339.
124. Chertow G.M., Block G.A., et al. Effect of Cinacalcet on Cardiovascular Disease in Patients Undergoing Dialysis. N Engl J Med 2012, 367:2482-2494. The EVOLVE trial investigators.
125. Mukherjee D. Spatial distribution of coronary artery thromboses in patients with chronic kidney disease: implications for diagnosis and treatment. Kidney Int 2009, 75:7-9.
126. Sedlis S.P., Jurkovitz C.T., Hartigan P.M., et al. Optimal medical therapy with or without percutaneous coronary intervention for patients with stable coronary artery disease and chronic kidney disease. Am J Cardiol 2009, 104:1647-1653. COURAGE study investigators.
127. Hemmelgarn B.R., Southern D., Culleton B.F., et al. Survival after coronary revascularization among patients with kidney disease. Circulation 2004, 110:1890-1895.
128. Charytan D.M., Li S., Liu J., et al. Risks of death and end-stage renal disease after surgical compared with percutaneous coronary revascularization in elderly patients with chronic kidney disease. Circulation 2012, 126(11 Suppl 1):S164-S169.
129. Bae K.S., Park H.C., Kang B.S., et al. Percutaneous coronary intervention versus coronary artery bypass grafting in patients with coronary artery disease and diabetic nephropathy: a single center experience. Korean J Intern Med 2007, 22:139-146.
130. Ix J.H., Mercado N., Shlipak M.G., et al. Association of chronic kidney disease with clinical outcomes after coronary revascularization: the arterial revascularization therapies study (ARTS). Am Heart J 2005, 149:512-519.
131. Zheng H, Xue S, Lian F, et al. Meta-analysis of clinical studies comparing coronary artery bypass grafting with percutaneous coronary intervention in patients with end-stage renal disease. Eur J Cardiothorac Surg (in press).
132. Loef B.G., Epema A.H., navis G., et al. Off-pump coronary revascularization attenuates transient renal damage compared with on-pump coronary revascularization. Chest 2002, 121:1190-1194.
133. Lamy A., Devereaux P.J., Prabhakaran D., et al. Off-pump or on-pump coronary-artery bypass grafting at 30 days. N Engl J Med 2012, 366:1489-1497.